Search results: (10000)
News Thromboprophylaxis in Cancer Patients − Results of Current Meta-Analysis
A recently published meta-analysis shows the benefits of thromboprophylaxis in cancer patients, with no increased risk of severe bleeding complications.
News Empagliflozin in the Treatment of Patients with Chronic Heart Failure
Unlike other antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization due to heart failure and the risk of severe renal events in patients with type 2 diabetes mellitus. The efficacy of the SGLT2 inhibitor empagliflozin directly in the treatment of patients with chronic heart failure with reduced ejection fraction was evaluated in the EMPEROR-Reduced clinical study, the recently published results of which we summarize in the following article.
News Intracranial Activity of Lorlatinib in Patients with Metastatic ALK-Positive NSCLC
Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor with significant antitumor activity against non-small cell lung cancer (NSCLC). According to the results of an international clinical study published in the Annals of Oncology, it shows very good efficacy in treating intracranial metastases in patients who experienced disease progression during therapy with second-generation ALK inhibitors.
News Perioperative substitution therapy in patients with vWD must be tailored
Even in cases of von Willebrand disease (vWD), available data supports the need for individualized approaches in ensuring surgical procedures to prevent FVIII accumulation and high factor consumption.
News Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease
A study published last year in the Journal of Thrombosis and Haemostasis presents the results of Dutch hematologists who created a pharmacokinetic model to refine the dosing of clotting factors during surgery in patients with von Willebrand disease (vWD).
News Safety and Effectiveness of Lurasidone in Adolescents with Schizophrenia
An open-label extension of a placebo-controlled study involving 271 patients aged 13–17 years with schizophrenia showed minimal impact on body weight, lipid levels, prolactin, and blood glucose during 2 years of treatment while maintaining and deepening the alleviation of schizophrenia symptoms.
News Can sartans improve clinical outcomes in hypertensive patients with COVID-19?
Dysfunction of the renin-angiotensin system (RAS) has been detected in patients with COVID-19. This finding led to the hypothesis that RAS inhibitors (RASi) could help these patients. To verify this, a retrospective study was conducted, the results of which we briefly summarize.
News Does idarucizumab reverse the anticoagulant effect of dabigatran regardless of renal function?
The drugs idarucizumab and dabigatran are excreted by the kidneys. The RE-VERSE AD study investigated whether the renal function of patients affects the extent of the reversing effect of idarucizumab on the effect of dabigatran.
News New Treatment Option for Metastatic Pancreatic Cancer – Pegylated Liposomal Irinotecan
The 2019 review article is dedicated to the use of nanoliposomal irinotecan, its toxicity, and its potential use in the treatment sequence of metastatic pancreatic ductal adenocarcinoma.
News Sport as an Important Part of the Life of Hemophiliacs
People with congenital bleeding disorders have very diverse approaches to sports and exercise. The possibility of preventing bleeding by administering safe and effective medications for these patients clearly supports engagement in an active physical life.
News Can Co-administration of Dabigatran with Antiretroviral Drugs Be Effective and Safe?
In 2019, the first results regarding the concurrent use of antiretroviral drugs and oral anticoagulants were published. This involved 14 patients with atrial fibrillation and HIV infection, in whom the concurrent administration of dabigatran with antiretroviral drugs was not associated with the occurrence of thromboembolic events or bleeding during follow-up lasting up to 40 months.
News Diabetic Nephropathy and COVID-19: Fatal Connection?
People with diabetes and diabetic kidney disease exhibit higher mortality and risk of severe illness in connection with COVID-19. The worse prognosis of these patients likely has multiple reasons; in the following overview, we will focus mainly on the cellular receptor of the SARS-CoV-2 virus – angiotensin-converting enzyme 2 (ACE2).
News Efficacy of Panitumumab in the Treatment of Refractory mCRC
A meta-analysis of 7 clinical trials showed that panitumumab therapy demonstrates a higher overall response rate compared to controls in patients with refractory metastatic colorectal cancer (mCRC).
News Current Results of Brigatinib in the Treatment of Lung Cancer
The results of the primary analysis showed a significant extension of PFS in patients with non-small cell lung cancer (NSCLC) treated with brigatinib compared to crizotinib. The recently published secondary analysis confirms these results.
News Impact of Lurasidone on Metabolic Functions Compared to Other Antipsychotics – Results of a Large Meta-Analysis
Antipsychotic therapy is associated with varying degrees of metabolic abnormalities in parameters of weight, lipid metabolism, and glucose metabolism. The presence of metabolic syndrome or isolated disorders of glucose and lipid metabolism further increases the risk of morbidity and mortality in patients with schizophrenia compared to the general population. Lurasidone is an antipsychotic indicated for the acute and maintenance treatment of schizophrenia. The advantage of this drug is its low risk of metabolic side effects, which has been confirmed in a recent large meta-analysis of clinical studies.
News Impact of Physiotherapy and Sports Activities on the Results of Movement Tests in Children with Hemophilia
At the 9th Hemophilia Academy, held online from October 5-7 in Budapest, a lecture by Mgr. Marie Katzerová from University Hospital Brno titled “Physiotherapy, Sports, and Hemophilia” aimed to elucidate the impact of physical activity on the results of movement tests in children with hemophilia.
News Real Impact of Lockdown on Asthma Treatment – EAACI Survey Results
Restrictions associated with the COVID-19 pandemic have had a significant impact on the treatment of chronic diseases such as asthma. A study published in the journal Allergy focused on evaluating treatment approaches for adult and pediatric patients with asthma during the coronavirus pandemic lockdowns.
News Efficacy and Safety of Axitinib in Higher Lines of Renal Carcinoma Treatment in Real Practice
Greek authors published a retrospective study from a single institution and demonstrated that axitinib is a safe and effective treatment option for metastatic renal carcinoma even in ≥ 3rd line treatment.
News Does dabigatran use in women with acute venous thromboembolism reduce the risk of uterine bleeding compared to warfarin?
The use of new oral anticoagulants (NOACs) in patients with deep vein thrombosis is associated with a more favorable safety profile compared to warfarin. However, direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) pose a higher risk of abnormal uterine bleeding. The study presented below compared the risk of this bleeding when using dabigatran (a direct thrombin inhibitor) and warfarin.
News Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics
The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, which is the reduction of the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus (T2DM) with high cardiovascular (CV) risk. Compared to placebo, empagliflozin reduced this risk by a relative 35%.
News Efficacy and Safety of Enoxaparin as Bridging Anticoagulant Therapy After Ventricular Assist Device Implantation
The implantation of a ventricular assist device has become an increasingly common method in the treatment of end-stage heart failure in recent years. The implantation of the device necessitates anticoagulant therapy. In the long term, warfarin is most often used according to guidelines, but there are no clear recommendations for early postoperative anticoagulant therapy. The aim of a clinical study published last year was to evaluate the efficacy and safety of enoxaparin as bridging anticoagulant therapy after device implantation within a 3-month postoperative period.
News Biosimilar MB02 as an Alternative to Bevacizumab in Lung Cancer Treatment
The STELLA clinical trial aimed to evaluate the efficacy, safety, and immunogenicity of MB02, a biosimilar to bevacizumab, in patients with advanced non-small cell lung cancer.
News Efficacy and Safety of Gefitinib in Combination with Chemotherapy vs. Chemotherapy Alone in the Treatment of Advanced NSCLC
Non-small cell lung cancer (NSCLC) remains a disease with high mortality. The meta-analysis presented below compared the efficacy and safety of gefitinib in combination with chemotherapy versus chemotherapy alone in the treatment of advanced NSCLC.
News Treatment of Metastatic Colorectal Cancer During the COVID-19 Pandemic
In the conditions of the coronavirus pandemic, it is difficult to maintain good accessibility to ongoing comprehensive oncological care, and thus the quality of life of patients. An international team of researchers focused their survey among oncologists on how the pandemic affects the goals of 3rd line therapy in patients with metastatic colorectal cancer (mCRC) in real clinical practice. The survey results were presented at this year's virtual congress on the treatment of gastrointestinal tumors of the European Society for Clinical Oncology (ESMO).
News Evaluation of Treatment Response in CLL
The size of lymph nodes, liver, spleen, blood cell counts, systemic symptoms... Changes in these indicators provide clear information on whether the disease of chronic lymphocytic leukemia (CLL) has progressed, stabilized, or if the patient has achieved partial or complete remission after therapy. An even deeper insight into what has happened at the cellular level in the human body is provided by the evaluation of minimal residual disease (MRD). Why is it meaningful to search for the remaining leukemic cells? How to identify them, in what material, and when? And is the information about MRD truly useful for all types and lines of treatment? The answers to these questions, along with other current data and information on the topic, are brought by the following presentation.